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Abstract
Background: Mycobacterium tuberculosis (Mtb) remains an unresolved threat resulting in great annual loss of life.
The role of B cells during the protective immunity to Mtb is still unclear. B cells have been described as effector
cells in addition to their role as antibody producing cells during disease.
Here we aim to identify and characterize the frequency of peripheral B-cell subpopulations during active
Tuberculosis and over treatment response. Analysis were done for both class switched (CS) and non-class switched
(NCS) phenotypes.
Methods: We recruited participants with active untreated pulmonary Tuberculosis, other lung diseases and healthy
community controls. All groups were followed up for one week from recruitment and the TB cases till the end of
treatment (month 6).
Results: Peripheral blood samples were collected, stained with monoclonal antibodies to CD19+ cells, Immunoglobulin
(Ig) M, plasma cells (CD 138+), marker of memory (CD27+), immune activation (CD23+) and acquired on a flow cytometer.
Circulating Marginal zone B cells (CD19+IgM+CD23−CD27+) and memory phenotypes are able to distinguish between TB
diagnosis and end of treatment. The frequency of mature B cells from TB cases are lower than that of other-lung diseases
at diagnosis. A subpopulation of activated memory B cells (CD19+IgM+CD23+CD27+) cells are present at the end of TB
treatment.
Conclusions: This study identified distinctive B cell subpopulations present during active TB disease and other lung
disease conditions. These cell populations warrants further examination in larger studies as it may be informative as cell
markers or as effectors/regulators in TB disease or TB treatment response.
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Background
Tuberculosis (TB), remains an unresolved threat that is
responsible for great mortality and morbidity in humans.
Its causative agent, Mycobacterium tuberculosis (Mtb),
was ultimately responsible for 9 million newly reported
cases and 1.5 million deaths during 2013 [1]. Although
great progress has been made on T cell based tuberculosis
research, it is imperative that new avenues have to be
explored and that previously underappreciated cell
types are re-evaluated for their roles during the tuber-
culosis infection with the expectation of bringing an
end to the epidemic. It is commonly accepted that B
cell and antibody-mediated responses confers protec-
tion against extracellular pathogens and that the
regulation and control of intracellular organisms are
through cellular immune mechanisms.
There is increasing evidence that demonstrate B cells
functioning as mediators (in both effector and regulatory
roles) of immunity outside of their classically designated
profession as the facilitators of humoral immunity. B cell
activation by Toll-like receptor (TLR) antigens or whole
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organisms (like BCG or Mtb) can lead to a range of out-
comes to the host, either by producing antibody, secreting
cytokines (including interleukin (IL)-6, IL-10, and inter-
feron (IFN)-gamma) or presenting antigen to naïve T
cells [2–5]. B cell responses are beneficial to the host
during infections and damaging during autoimmune
disease. Conversely, B cells have the capacity to limit the
hosts defence (inflammatory response) against pathogens
and shield against autoimmune pathologies. This demon-
strates that B cells can have distinct roles as drivers and
regulators of immunity depending on the functional
properties they gain following receptor activation and
differentiation.
Although ongoing studies and literature supports the
functional role of B cells during TB [6], the respective
change in the frequency of the circulating B cell repertoire
during active Mtb infection remains a topic for discussion
as some studies report either a significant decrease [7] or
increase [8] of peripheral blood B cell populations in ac-
tively infected patients.
Immuno-phenotyping has proven to be a very useful
tool in the identification, monitoring and management
of various clinical diseases [9–11]. Although recent pub-
lications have sought to develop in depth multicolour
flow cytometric panels for the accurate delineation of
various lymphocyte populations and subpopulations
(including B cells) during immunodeficiencies [12, 13],
very few studies exist that specifically assess immune-
phenotypic change during active Mycobacterium tuber-
culosis infection [7, 14]. Little is known about the
immune-phenotypic change of the B cell lineage during
active Mtb as current literature largely focuses on the
general B cell presence (primarily looking at CD19+ B
cells only) [7, 14], rather than on an in-depth analysis
of various populations and subpopulations. This results
in a lack of knowledge pertaining to changes in B cell
populations implicated in effector roles such as circulating
memory B cells or plasma populations. It also does not
elucidate the current activation state of B cells nor the ex-
pression of surface molecules, thus highlighting the need
for further investigation regarding this matter.
In this brief preliminary report, a total of 96 participant
samples spanning three groups (tuberculosis – active in-
fection; 52 samples, other-lung disease; 24 samples, and
healthy community controls; 20 samples) and various time
points relating to treatment were used to assess the B cell
repertoire in detail with the hope of identifying unique
phenotypic differences between the groups that could suf-
fice as biomarkers of disease. The primary contribution of
this data would be to map the phenotypic distribution of
B cells between these groups with a vast range, as it would
include phenotypes for both IgM+ and IgM− B cells. The
actual isotype linked to the IgM− phenotypes have not
been determined for this study.
Methods
Patients
This study was done in the Western Cape Province of
South Africa where a 2003 report showed that the TB
detection rate was 678/100,000 population [15]. Previous
publications have defined the characteristics associated
with the economically depressed and disadvantaged
metropolitan population of homogeneous ethnicity pri-
marily found in the Western Cape Province, presenting
high incidence rates of Mtb and transmission [16, 17].
The study participants included all attendees of the
Infectious Diseases Clinics at Tygerberg Hospital, all
community members of surrounding areas including
Ravensmead, Uitsig, Adriaanse, Elsiesriver and local health
care clinics. A total of 96 HIV negative participants, span-
ning three groups, were recruited for this study. All the
study participants were also negative for Hep B. Fifty-two
had active drug susceptible tuberculosis disease (on stand-
ard TB treatment regime) (TB disease status was con-
firmed by two separate positive sputum smear tests and a
PCR for DNA of bacteria of the Mtb complex, by utilising
the GeneXpert platform), 20 were healthy community
controls (Mtb culture negative, Quantiferon test positive,
therefor assuming latently infected with Mtb) and the
third group consisted of 24 other-lung disease (OLD) pa-
tients. These OLD patients were all TB and HIV negative
and presented with at least one of the following: a) febrile
illness with chest symptoms, b) radiographic evidence of
viral or bacterial pneumonia, c) bronchiectasis with acute
exacerbation, or d) acute exacerbation of asthma or COPD
(chronic obstructive pulmonary disease). The OLD pa-
tients were not on any steroid treatment at the time on
recruitment. Table 1 summarizes the demographic data
of study participants.
B cell phenotyping
Peripheral blood samples from the two control groups
and patients were collected on various scheduled visits
which included diagnoses, day 7 on treatment and at
week 24 (end of TB treatment). White blood cells were
obtained by subjecting each sample to a red blood cell
lysing step using BD FACSlyse solution (BD Bioscience
Pharmingen – San Jose, CA, USA). Leukocytes were
stained following a standard procedure with anti-human
CD3 (APC/Cy7, clone HIT3a), anti-human CD4 (PerCP/
Cy5.5, clone OKT4), anti-human CD8a (Brilliant Violet
510, clone RPA-T8), anti-human CD19 (PE/Cy7, clone
HIB19), anti-human CD23 (FITC, clone EBVCS-5), anti-
human CD27 (PE, clone M-T271), anti-human CD138
(APC, clone DL-101) and anti-human IgM (Brilliant
Violet, clone MHM-88). All antibodies were purchased
from BioLegend (San Diego, California, United States of
America). A total of 100,000 lymphocytes/sample were
acquired on a FACS Canto II (BD Biosciences). All post
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acquisition analysis was done with FlowJo Software v10
(Tree Star Inc.) and the frequencies of the parent popula-
tions determined (Fig. 1). The assessed phenotypes (Fig. 1
showing the gating strategy using an treated TB case) were
defined as follows: (1) Mature B cells (CD19+IgM+), (2)
Activated B cells (CD19+IgM+CD23+), (3) Naïve B cells
(CD19+IgM+CD23+CD27+), (4) Circulating Marginal Zone
(MZ) B cells (CD19+IgM+CD23−CD27+), (5) Memory B
cells (CD19+IgM+CD27+), (6) Plasmablasts with memory
phenotype B cells (CD19+IgM+CD27++) (7) Total
plasma cells (CD19+IgM+CD138+), (8) Plasmablasts cells
(CD19+IgM+CD27+CD138+) and (9) Plasmablasts with
memory phenotype B cells (CD19+IgM+CD138+CD27++).
All IgM+ phenotypes are referred to as non-class switched
(NCS) and IgM− phenotypes as class switched (CS) in text.
Statistical analysis
Differences in the frequency of B cell subsets between
the groups were analysed using the non-parametric ana-
lysis with a Mann-Whitney correction and performed by
Dr Justin Harvey (Stellenbosch University). All analysis
were performed with the Statistica 12 software (Statsoft,
Ohio, USA).
Fig. 1 Flow cytometric gating strategy to identify the different peripheral B cell phenotypes. Populations for both IgM+ and IgM- are shown.
MZ =marginal zone
Table 1 Clinical and demographic data of the study participants
Group Age Range Gender-ratio (Male: Female) BMI HIV (+) Other-lung Disease Diagnosisa TB Type
Tuberculosis (n = 52) 18–50 3 M : 1 F 17.8 ± 1.7 0 n/a Pulmonary
HC (n = 20) 19–50 4 M : 1 F 22.9 ± 6.3 0 n/a n/a
OLD (n = 24) 25–64 1 M : 1 F 27.4 ± 8.2 0 Pneumonia (n = 10) n/a
Asthma (n = 2)
COPD (n = 1)
Pleural Effusion, Reactive (n = 1)
OLD other-lung disease, HC healthy community control, BMI body mass index, COPD chronic obstruction of airways disease. aAll cases had to include symptoms
of fever, coughing and other symptoms that would classify the case as acute and of exacerbated nature. Patients on systemic steroid therapy was excluded from
the study
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Results and discussion
Circulating marginal zone B cells and memory phenotypes
distinguish between TB diagnosis and end of treatment
We firstly aimed to identify phenotypes that were signifi-
cantly different at diagnosis and the end of treatment
(week 24). In Fig. 2 it is seen that the CD27high memory
B cells (CD19+IgM+CD27++), p = 0.02880, and plasmablasts
B cells (CD19+IgM+CD138+CD27+), p = 0.00389, popu-
lations were significantly higher at diagnosis as when
compared to levels at the end of treatment. Sebina et
al. [18] observed that UK donors who previously lived
in, or visited areas denoted as highly TB-endemic had
higher frequencies of memory B cells in their periph-
eral blood as compared to their counterparts who have
not. This study also reported that BCG elicited the pro-
duction of long-lived mycobacteria-specific memory B
cells [18], which supports the notion of high observed
frequencies of memory B cells at diagnosis as BCG vac-
cination is a common practice at birth in South Africa.
It has been shown that the maintenance of memory B
cells are dependent on the presence of antigen, and that
they are lost within 10–12 weeks following its absence
[19]. Although this is opposite to other publications
stating the longevity of B cells [18, 20–22], it corre-
sponds to the observed result of lower memory B cell
frequencies at the end of treatment. The high numbers
of TB-specific (or BCG-specific, or mycobacteria-
specific) memory B cells might be maintained in this
population due to the continual exposure to antigen
(either M.tb exposure in this high prevalence setting, or
environmental or non-tuberculous mycobacterial ex-
posure). It is reasonable that the decrease of memory B
cells towards the end of treatment don’t relate to a
complete loss of memory B cells, but rather represents
an overall decrease in line with the reduction of bacter-
ial burden. Figure 3 shows that memory based B cell
phenotypes were significant in the CS cohort as well
with memory B cells (CD19+IgM−CD27+); p = 0.01398,
plasmablasts B cells (CD19+IgM−CD138+CD27+); p =
0.00968 and plasmablasts with memory phenotype a
(CD19+IgM−CD138+CD27++); p = 0.03616. This continual
significance in both NCS and CS phenotypes strengthens
their importance as distinguishing factors. Circulating
Marginal zone B cells (CD19+CD27+CD23−) were also
significant in both NCS (p = 0.04680) and CS (p =
0.02138) analyses and between groups over time (Fig. 4).
Together these results warrants further research into
these phenotypes as potential biomarkers for treatment
response.
Circulating marginal zone- and Mature B cells can
distinguish TB from other-lung diseases at diagnosis
In the attempt to identify phenotypes that were unique to
tuberculosis when compared to other-lung based diseases,
two results showed to be significant. The first was NCS
marginal zone (MZ) B cells (CD19+IgM+CD27+CD23−)
with p = 0.02092 and secondly CS mature B cells were
significant with p = 0.00026 (Fig. 4). With both of these
phenotypes significantly lower in peripheral circulation
during active TB disease (especially the CS mature B
cells), it raises the question whether TB actively suppresses
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Fig. 2 IgM+ B cell phenotypes that are significantly different at TB
diagnosis and end of treatment (W24). Vertical bars denote 95 %
confidence. Dx = diagnosis, W24 = week 24
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the B cell repertoire during disease. The NCS mature B
cell repertoire does not recover to baseline levels during
the first week of treatment as one would expect (in line
with chemotherapeutic treatment alleviating bacterial
burden). These findings support the notion that there
is a possible underlying mechanism exploited by Mtb
that could be crucial to the management of the infec-
tion as both MZ and mature B cells are implicated in
effector functions of the adaptive immune system, as
seen with the overexpression of programmed death 1
(PD-1) on lymphocyte frequencies during active TB in-
fection [23].
Class switched and non-class switched mature B cells
distinguish between tuberculosis, other-lung based
diseases and healthy controls
Class switched mature B cells from participants with ac-
tive TB are present in significantly different levels when
compared to other-lung diseases (p = 0.043711) and the
healthy control group (p = 0.024488) (Fig. 5). Mature B
cells were not only able to distinguish between these
groups in the class switched category, but also in the
non-class switched category where the difference be-
tween TB and OLD was highly significant (p = 0.000016)
and between TB and the healthy control group where
p = 0.025939 (not shown)). An interesting observation
is that the class switched mature B cells from TB is
present at higher frequencies when compared to the
OLD group (Fig. 5), but that the inverse is observed
with non-class switched mature B cells where they are
present in significantly lower levels when compared to
the OLD group (not shown). This would suggest that a
strong preference is displayed towards class switched
mature B cells during active tuberculosis. The differences
present in the CS and NCS mature B cells are consistent
when compared during the first week of treatment (not
shown), where the NCS mature B cells are present in
higher frequencies as when compared to the class switched
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Fig. 3 IgM- B cell phenotypes that are significantly different between TB diagnosis and end of treatment (W24). Vertical bars donate 95 %
confidence. Dx = diagnosis, W24 = week 24
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mature B cells. Further in this study, NCS activated B cells
in TB could distinguish from OLD (p = 0.008391), but not
from healthy controls (p = 0.122877) (Fig. 6). This result
identifies another combination of markers that could be
used to distinguish TB from other lung based diseases and
should be further investigated as a measure in the early
diagnosis of TB.
Conclusion
This pilot study identified unique variations in the B cell
repertoire during active tuberculosis infection when
compared to healthy controls, other-lung based diseases
and over the course of TB treatment. The first observa-
tion of memory-based phenotypes being the major dis-
tinguishers between diagnosis and end of treatment in
both class switched and non-class switched phenotypes
holds promise as markers for treatment response. The
second important finding of this study is that circulat-
ing marginal zone B cells could not only distinguish
between TB diagnosis and the end of treatment, but also
has significantly different frequencies when compared to
other-lung based diseases making it a candidate as
biomarker for not only treatment response, but distin-
guishing active TB disease from other-lung based diseases.
The observation that NCS and CS mature B cells could
best distinguish between TB and the two control groups
(healthy controls and other lung diseases) at diagnosis,
but that their respective peripheral frequencies are present
at an inverse level. Taken together, these results show that
mainly B cell phenotypes implicated in activation and
subsequent effector functions are influenced by TB and
warrants further research to confirm their potential as bio-
markers for TB disease and treatment response. These
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Fig. 4 a IgM+ Marginal Zone B cells and b IgM- Mature B cells are significantly different between TB and OLD at diagnosis. TB = tuberculosis,
OLD = other-lung disease. c Frequency distribution of circulating Marginal Zone B cells between groups over time. Dx = diagnosis, d7 = day 7
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results are further strengthened if the assumption holds
that only 10 % of the ongoing immunologic response is
represented in the peripheral blood when compared to
the site of disease, namely the lungs. Further studies is
thus needed to replicate this experiment on broncho-
alveolar lavage (BAL) fluid from active TB diseased partici-
pants and other lung diseases to ascertain if the phenotype
remains the same. Although the results from the BAL
fluid experiment might give a better representation of the
on-site B cell frequencies, the challenges associated
with obtaining the bio fluid and characterisation of the
(mostly activated) cells could hamper the process of
finding biomarkers of disease or TB treatment
response.
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Fig. 5 IgM+ Mature B cells are significantly different at diagnosis when compared to other disease states. P-Values represent significant difference,
where an alpha level of 95 % is used. TB = tuberculosis, OLD = other-lung disease, HC = healthy control
Fig. 6 IgM+ Activated B cells are significantly different at diagnosis when compared to other disease states. An alpha level of 95 % was used in
the LSD test, whose results is displayed in the accompanying table. P- Values show significance between specific comparisons. TB = tuberculosis,
OLD = other-lung disease, HC = healthy control
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